Related Experiment Video
Updated: May 11, 2026

Correlating Gene-specific DNA Methylation Changes with Expression and Transcriptional Activity of Astrocytic KCNJ10 (Kir4.1)
Published on: September 26, 2015
Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic
Sally R Lambert1, Hendrik Witt, Volker Hovestadt
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. sl575@cam.ac.uk
Insights
Pilocytic astrocytomas (PAs) in children show distinct DNA methylation patterns based on location. These patterns reveal potential region-specific origins and disrupt key developmental genes, impacting future treatments.
Area of Science:
- Neuro-oncology
- Epigenetics
- Developmental Biology
Background:
- Pilocytic astrocytomas (PAs) are common pediatric brain tumors with poorly understood development beyond MAPK pathway alterations.
- PAs cause significant morbidity in children, including chronic neurological deficits.
Purpose of the Study:
- To comprehensively map DNA methylation profiles of pilocytic astrocytomas.
- To identify epigenetic differences related to tumor location and developmental gene regulation.
Main Methods:
- Analysis of DNA methylation using Illumina 450K microarrays on 62 PAs and 7 normal cerebellum samples.
- Integration with transcriptome microarray data to correlate methylation with gene expression.
- Identification of differentially methylated genes and association with SUZ12 binding sites.
Main Results:
- Two distinct subgroups of PAs were identified, correlating with tumor location (infratentorial vs. supratentorial).
- Key neural developmental genes, including NR2E1 and EN2, showed differential methylation between subgroups.
- Unexpected positive correlation between DNA methylation and gene expression was observed, with methylation often occurring outside promoter regions.
- Enrichment of differentially methylated developmental genes in PAs compared to normal cerebellum.
- Association between differentially methylated genes and SUZ12 binding sites, suggesting Polycomb Repressor Complex 2 (PRC2) disruption.
Conclusions:
- PA development may involve region-specific cells of origin, influenced by location.
- Epigenetic dysregulation of key developmental genes is implicated in PA tumorigenesis.
- Findings suggest potential differences in therapeutic targets and drug sensitivity based on tumor location, with implications for clinical trials.
Abstract:
Pilocytic astrocytomas (PAs) are the most common brain tumors in pediatric patients and can cause significant morbidity, including chronic neurological deficiencies. They are characterized by activating alterations in the mitogen-activated protein kinase pathway, but little else is known about their development. To map the global DNA methylation profiles of these tumors, we analyzed 62 PAs and 7 normal cerebellum samples using Illumina 450K microarrays. These data revealed two subgroups of PA that separate according to tumor location (infratentorial versus supratentorial), and identified key neural developmental genes that are differentially methylated between the two groups, including NR2E1 and EN2. Integration with transcriptome microarray data highlighted significant expression differences, which were unexpectedly associated with a strong positive correlation between methylation and expression. Differentially methylated probes were often identified within the gene body and/or regions up- or downstream of the gene, rather than at the transcription start site. We also identified a large number of differentially methylated genes between cerebellar PAs and normal cerebellum, which were again enriched for developmental genes. In addition, we found a significant association between differentially methylated genes and SUZ12 binding sites, indicating potential disruption of the polycomb repressor complex 2 (PRC2). Taken together, these data suggest that PA from different locations in the brain may arise from region-specific cells of origin, and highlight the potential disruption of key developmental regulators during tumorigenesis. These findings have implications for future basic research and clinical trials, as therapeutic targets and drug sensitivity may differ according to tumor location.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
06:47In Utero Electroporation of Multiaddressable Genome-Integrating Color (MAGIC) Markers to Individualize Cortical Mouse Astrocytes
Published on: May 21, 2020